Diabetes
MINNEAPOLIS - The University of Minnesota and the Mayo Clinic announced Tuesday they hope to raise between $250 million and $350 million for expanded research into treatments and a cure for diabetes.
SPLIT DECISION: U.S. health officials restricted access to the controversial diabetes pill Avandia Thursday, even as European regulators ordered it off the market based on heart attack risks.
U.S. health regulators dealt a major blow to the controversial diabetes pill Avandia Thursday, requiring doctors and patients to sign consent forms before starting a prescription of the drug.
European regulators ordered the diabetes drug Avandia off the market and the Food and Drug Administration placed stringent restrictions on its use in the United States, saying heart attack risks associated with the former blockbuster are too great a safety concern to continue its use for most people.
European health regulators have banned sales of the once-blockbuster diabetes drug Avandia because of evidence it raises the risk of heart attack, but doctors in the U.S.
More News
- European agency says Avandia should be pulled
- Sanofi reports positive results with diabetes drug
- FDA reviewing cancer risk with diabetes pill Actos
- UK regulators want Avandia diabetes pill pulled
- Diabetes now tops Vietnam vets' claims
- FDA issues hold on much-debated Avandia study
- Earnings Preview: Bristol-Myers to discuss R&D
- FDA panel: Diabetes drug should stay on market
- Avandia debate spotlights key FDA decision makers
- Diabetes pill controversy shows rift in FDA ranks
- FDA review spotlights heart risk of diabetes pill
- European agency to review safety of GSK's Avandia
- Diabetics eye obesity surgery to tame blood sugar
- When is a drug too risky to stay on the market?
- Diabetes drug risks reported ahead of FDA hearing
- FDA OKs Abbott's new diabetes testing strips
- J&J cuts 2 deals for diabetes treatment
- AstraZeneca wins 1st trial over alleged drug harm
- Amylin shares up on FDA response for diabetes drug
- FDA asks for risk plan info on diabetes drug
- Scientists try to break fat-and-disease link
- California county sues Glaxo over diabetes drug
- Hot tip: Target inflammation to ease obesity ills
- FDA to review Biodel diabetes drug candidate
- Glaxo defends handling of Avandia heart risks
- Senate report: Avandia maker knew of cardiac risks
- Sector Snap: FDA nod boosts diabetes drugmakers
- Ahead of the Bell: Amylin Pharmaceuticals
- FDA approves Novo-Nordisk's diabetes drug Victoza
- J&J, charity to start testing artificial pancreas
- FDA confirms benefits of Crestor in more patients
- Study tests blood pressure drugs for diabetics
